Infinity Pharmaceuticals, Inc. Appointed Mr. Sujay Kango to Board of Directors and as a member of the Compensation Committee of the Board effective March 30, 2022. Mr. Kango is an experienced executive with more than 25 years of experience in the pharmaceutical and biotechnology industries. He has been instrumental in successfully transforming earlier stage organizations to later-stage development and commercial global biotech companies.

He joined Acceleron Pharma in 2018, where he most recently served as the executive vice president and chief commercial officer. Under his leadership the team launched luspatercept, led multiple rare disease franchises, and established N.America and international presence for Acceleron. He played a key leadership role in Acceleron's $11.5 billion acquisition by Merck in the second half of 2021.